Search Result

Results for "

human hepatocellular carcinoma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Acetyl-CoA Carboxylase (1) Acyltransferase (1) Adrenergic Receptor (1) Akt (5) Aminotransferases (Transaminases) (1) Amyloid-β (1) Anaplastic lymphoma kinase (ALK) (1) AP-1 (1) Apoptosis (40) Aryl Hydrocarbon Receptor (2) Atg8/LC3 (3) Autophagy (6) Bacterial (3) Bcl-2 Family (10) BCL6 (4) Beclin1 (1) Biochemical Assay Reagents (1) Caspase (15) Cathepsin (2) CCR (1) CD44 (1) CDK (5) Ceramidase (1) Checkpoint Kinase (Chk) (1) Chloride Channel (1) Cholinesterase (ChE) (2) CMV (1) COX (1) CTLA-4 (1) CXCR (1) Cyclin G-associated Kinase (GAK) (1) Cyclophilin (1) Cytochrome P450 (3) DNA/RNA Synthesis (2) Drug Derivative (9) Drug Metabolite (1) E1/E2/E3 Enzyme (1) EGFR (1) Endogenous Metabolite (9) Epigenetic Reader Domain (1) ERK (10) Estrogen Receptor/ERR (1) FAK (2) Ferroptosis (2) FGFR (15) Fungal (1) Glutathione S-transferase (1) Glycoprotein VI (6) Glycosyltransferase (1) HBV (1) HCV (1) Heme Oxygenase (HO) (1) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (1) Histone Methyltransferase (1) HIV (1) HSP (2) IFNAR (1) iGluR (3) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (1) Insulin Receptor (1) Integrin (2) Interleukin Related (10) JNK (2) Keap1-Nrf2 (1) MDM-2/p53 (1) MEK (2) MetAP (2) Microtubule/Tubulin (5) Mitochondrial Metabolism (2) mTOR (9) Na+/K+ ATPase (1) NAMPT (1) NF-κB (9) Opioid Receptor (1) P-glycoprotein (1) P2Y Receptor (1) p38 MAPK (7) p97 (1) Parasite (2) PARP (9) PERK (1) Phosphatase (1) PI3K (3) Pim (1) PNPLA3 (1) Polo-like Kinase (PLK) (2) Pregnane X Receptor (PXR) (1) PROTACs (3) Protein Arginine Deiminase (1) Raf (4) RAR/RXR (1) Ras (1) Reactive Oxygen Species (ROS) (6) Reference Standards (6) Small Interfering RNA (siRNA) (1) STAT (4) TGF-beta/Smad (1) TNF Receptor (4) Toll-like Receptor (TLR) (2) VD/VDR (1) VEGFR (2) YAP (1)
By Research Areas:	Cancer (110) Cardiovascular Disease (2) Infection (11) Inflammation/Immunology (16) Metabolic Disease (8) Neurological Disease (8)
Oligonucleotides:	CpG ODNs (1) siRNA drugs (1) siRNAs (1)

125

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Glycochenodeoxycholic acid 5 Publications Verification Chenodeoxycholylglycine	Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase	Metabolic Disease Cancer
Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .

Glycochenodeoxycholic acid sodium salt 5 Publications Verification Chenodeoxycholylglycine sodium salt; Sodium glycochenodeoxycholate	Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase	Metabolic Disease Cancer
Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .

2-Deoxy-2-fluoro-L-fucose 1 Publications Verification	Glycosyltransferase	Cancer
2-Deoxy-2-fluoro-L-fucose, an L-fucose analog, is a fucosylation inhibitor. 2-Deoxy-2-fluoro-L-fucose inhibits de novo synthesis of GDP-fucose in mammalian cells. Fucosylation is a relatively well-defined biomarker for progression in many human cancers; for example, pancreatic and hepatocellular carcinoma .

Codrituzumab 1 Publications Verification GC33; RO5137382	Glycoprotein VI	Cancer
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (K_d of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .

Arenobufagin 4 Publications Verification	Apoptosis Autophagy PI3K Akt mTOR PARP Caspase Atg8/LC3	Cancer
Arenobufagin is a natural bufadienolide that can be extracted from toad venom. Arenobufagin can induce apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Arenobufagin has potent antineoplastic activity against HCC HepG2 cells as well as corresponding multidrug-resistant HepG2/ADM cells. Arenobufagin can inhibit VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway .

Nε-(Carboxymethyl)-L-lysine 1 Publications Verification CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine	Polo-like Kinase (PLK) ERK NF-κB	Cancer
Nε-(Carboxymethyl)-L-lysine (CML) is an orally active advanced glycation end product. Nε-(Carboxymethyl)-L-lysine upregulates the expression of PLK1 and CEP20, and induces the activation of RAGE and ERK/NFκB. Nε-(Carboxymethyl)-L-lysine drives centrosome amplification. Nε-(Carboxymethyl)-L-lysine induces malignant transformation of hepatocytes and promotes the development of hepatocellular carcinoma. Nε-(Carboxymethyl)-L-lysine induces epithelial-mesenchymal transition in osteosarcoma cells and enhances their migration and invasion properties .

Neriifolin 17β-Neriifolin	Atg8/LC3 Na+/K+ ATPase Apoptosis Beclin1	Cardiovascular Disease Inflammation/Immunology Cancer
Neriifolin, a CNS-penetrating cardiac glycoside, is an inhibitor of the Na ⁺, K ⁺-ATPase. Neriifolin can target beclin 1, inhibits the formation of LC3-associated phagosomes and ameliorates experimental autoimmune encephalomyelitis (EAE) development. Neriifolin induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells ^[2.

Peiminine Maximum Cited Publications 7 Publications Verification Verticinone; Raddeanine	Autophagy Caspase Bcl-2 Family PARP p38 MAPK ERK NF-κB Apoptosis	Inflammation/Immunology Cancer
Peiminine is a compound that can be isolated from Bolbostemma paniculatum (Maxim) Franquet (Cucurbitaceae family). Peiminine can induce apoptosis in human hepatocellular carcinoma HepG2 cells through both extrinsic and intrinsic apoptotic pathways. Peiminine has anti-inflammatory, anticancer, anti-osteoporosis, cardioprotective and other activities in many animal models .

Pyruvate Carboxylase-IN-1 2 Publications Verification	Mitochondrial Metabolism	Cancer
Pyruvate Carboxylase-IN-1 (compound 37) is a potent pyruvate carboxylase inhibitor with antiproliferative activity. The IC₅₀ values of pyruvate carboxylase-IN-1 against PC in cell lysates and cells are 0.204 and 0.104 μM, respectively .

Rapastinel 1 Publications Verification GLYX-13	iGluR ERK mTOR	Neurological Disease Cancer
Rapastinel (GLYX-13) is a potent NMDAR modulator capable of crossing the blood-brain barrier, and it exhibits extremely high affinity for human NMDAR (EC₅₀=0.0017-9.9 nM). Rapastinel enhances ERK signaling and activates the mTOR pathway, thereby upregulating the expression of BDNF and VGF, and inducing significant neuroplastic changes such as enhanced LTP and increased mature dendritic spine density in the hippocampus. Rapastinel moderately elevates the efflux of dopamine, norepinephrine and 5-HT in the prefrontal cortex, and uniquely avoids side effects of traditional antidepressants such as dissociation, addiction or sedation. Rapastinel is applicable to the research of major depressive disorder and hepatocellular carcinoma .

Ivuxolimab	Interleukin Related	Cancer
Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4 ⁺ and CD8 ⁺ T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc .

Fumonisin B2	Ceramidase Acyltransferase	Infection Cancer
Fumonisin B2 is a selective ceramide synthase inhibitor and carcinogenic mycotoxin with toxicity comparable to that of Fumonisin B1 (HY-N6719). Fumonisin B2 inhibits de novo sphingolipid biosynthesis by blocking the amide bond formation between fatty acids and dihydrosphingosine, which leads to a massive intracellular accumulation of free dihydrosphingosine, altered sphingosine levels, subsequent inhibition of cell proliferation, and induction of cell death. Fumonisin B2 is used to investigate the pathogenesis of diseases associated with Fusarium verticillioides contamination, including equine leukoencephalomalacia, porcine pulmonary edema syndrome, human esophageal cancer, and rat hepatocellular carcinoma .

Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) 1 Publications Verification	CCR HIV	Infection Inflammation/Immunology Cancer
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV .

ODN M362 sodium	Toll-like Receptor (TLR) Apoptosis Interleukin Related TNF Receptor IFNAR	Inflammation/Immunology Cancer
ODN M362 sodium is a TLR9 agonist that acts as a vaccine adjuvant. ODN M362 sodium activates mouse splenocytes, induces apoptosis in human hepatocellular carcinoma cells, upregulates proinflammatory cytokines in human hepatocellular carcinoma cells, and inhibits the proliferation of human hepatocellular carcinoma cells. ODN M362 sodium upregulates the expression of TLR9/TLR6, activates downstream signaling pathways via IRAK4 and IRF7, and strongly amplifies antigen-specific cellular immune responses to participate in innate immune activation. ODN M362 sodium can be used in research related to hepatocellular carcinoma and breast cancer .

Ascrinvacumab 2 Publications Verification Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab); PF-03446962; GT-90001C	Anaplastic lymphoma kinase (ALK)	Cancer
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a K_d value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .

PF-07853578	PNPLA3	Metabolic Disease Cancer
PF-07853578 is an orally active PNPLA3 modulator. PF-07853578 significantly reduces human PNPLA3-I148M protein levels and effectively decreases hepatic triglyceride content by reducing this mutant protein. PNPLA3 degrader-1 can be used in the research of liver cirrhosis and hepatocellular carcinoma .

Anti-pan-Glypican Antibody (HS20)	Glycoprotein VI	Cancer
Anti-pan-Glypican Antibody (HS20) is a kind of human IgG1 κ human antibody, targeting to human pan-Glypican. Anti-pan-Glypican Antibody (HS20) can neutralize the heparan sulfate (HS) chains on GPC3 thereby disrupting the Wnt3a-GPC3 interactions leading to blockade of the Wnt3a/β-catenin signaling. Anti-pan-Glypican Antibody (HS20) can be used for the research of cancer, such as hepatocellular carcinoma (HCC) .

MS934	PROTACs MEK Raf	Cancer
MS934 is a novel improved VHL-recruiting MEK 1/2 PROTAC degrader. MS934 also degrades CRAF. MS934 can be used for the research of variety of human cancers, such as melanoma, nonsmall cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma (Pink: Target protein ligand (HY-168288); Black: linker (HY-168289); Blue: E3 ligase ligand (HY-112078)) .

Pim-1 kinase inhibitor 2 1 Publications Verification	Pim Caspase Bcl-2 Family Apoptosis	Cancer
Pim-1 kinase inhibitor 2 is a PIM-1 kinase inhibitor with a human IC₅₀ of 0.63 μM. Pim-1 kinase inhibitor 2 exhibits high selectivity for cancer cells over normal cells. Pim-1 kinase inhibitor 2 induces apoptosis, increases active caspase-3 levels, upregulates BAX, downregulates Bcl-2, and elevates the Bax/Bcl-2 ratio. Pim-1 kinase inhibitor 2 suppresses cancer cell proliferation and induces cell cycle arrest. Pim-1 kinase inhibitor 2 can be used for the research of prostate carcinoma, hepatocellular carcinoma, and breast adenocarcinoma .

Osbond acid all-cis-4,7,10,13,16-Docosapentaenoic acid	Biochemical Assay Reagents	Others
Docosapentaenoic acid (DPA) is a 22-carbon fatty acid found in fish oil. It is a minor component of total serum unsaturated fatty acids in humans, ranging from 0.1% to 1%, and increasing with dietary supplementation. all-cis-4,7,10,13,16-DPA, also known as Austrian acid, is an isomer of DPA. It is an omega-6 fatty acid formed by the extension and desaturation of arachidonic acid. During fatty acid desaturase syndrome, levels of this fatty acid may be reduced, which may affect development. Upregulated hepatic elongate expression of very long fatty acid protein 6 and elevated levels of very long chain fatty acids, including all-cis 4,7,10,13,16-DPA, are characteristic of nonalcoholic steatohepatitis, a precancerous disease of hepatocellular carcinoma.

Hericenone A	Drug Derivative	Cancer
Hericenone A is an isoindolinone found in the fruiting bodies of Hericium erinaceus. Hericenone A exerts cytotoxic activity against cancer cells. Hericenone A can be used for the research of cancer, such as metastatic human hepatocellular carcinoma .

NF340	P2Y Receptor Interleukin Related NF-κB Reactive Oxygen Species (ROS)	Inflammation/Immunology
NF340 is a P2Y11 receptor inhibitor with a pIC₅₀ of 7.3-7.7 against human P2Y11 receptor, and it exhibits high selectivity over other P2Y family receptors. NF340 binds to the ATP-binding amino acid residues of the P2Y11 receptor to inhibit its activity, block nociceptive activity, and reduce spinal dorsal horn P2Y11 receptor upregulation induced by spinal nerve injury. NF340 attenuates the NFκB signaling pathway activated by IL-1β by decreasing IκBα phosphorylation, nuclear p65 accumulation, and NFκB promoter activity. NF340 inhibits IL-1β-induced pro-inflammatory cytokine expression, reduces intracellular ROS and 4-HNE levels, and suppresses IL-1β-induced matrix metalloproteinase expression in primary fibroblast-like synoviocytes. NF340 inhibits ATP-induced elevation of intracellular Ca ²⁺ concentration and cell migration in human hepatocellular carcinoma cells. NF340 can be used in the research of neuropathic pain, myocardial ischemia/reperfusion injury, inflammatory pain, rheumatoid arthritis, and hepatocellular carcinoma .

Amsilarotene TAC-101; Am 555S	RAR/RXR Apoptosis	Cancer
Amsilarotene (TAC-101; Am 555S), an orally active synthetic retinoid, has selective affinity for retinoic acid receptor α (RAR-α) binding with K_i of 2.4, 400 nM for RAR-α and RAR-β. Amsilarotene induces the apoptotic of human gastric cancer, hepatocellular carcinoma and ovarian carcinoma cells. Amsilarotene can be used for the research of cancer .

Garcinone E	Apoptosis	Cancer
Garcinone E is a natural xanthone found in the rind of the mangosteen fruit. Garcinone E induces apoptosis and inhibits cancer cell migration. Garcinone E has anticancer effects on different human cancer cell lines, including colorectal, breast, and hepatocellular carcinomas .

Rapastinel Trifluoroacetate 1 Publications Verification GLYX-13 Trifluoroacetate	iGluR mTOR ERK	Neurological Disease
Rapastinel (GLYX-13) Trifluoroacetate is a potent NMDAR modulator capable of crossing the blood-brain barrier, and it exhibits extremely high affinity for human NMDAR (EC₅₀=0.0017-9.9 nM). Rapastinel Trifluoroacetate enhances ERK signaling and activates the mTOR pathway, thereby upregulating the expression of BDNF and VGF, and inducing significant neuroplastic changes such as enhanced LTP and increased mature dendritic spine density in the hippocampus. Rapastinel Trifluoroacetate moderately elevates the efflux of dopamine, norepinephrine and 5-HT in the prefrontal cortex, and uniquely avoids side effects of traditional antidepressants such as dissociation, addiction or sedation. Rapastinel Trifluoroacetate is applicable to the research of major depressive disorder and hepatocellular carcinoma .

Glycochenodeoxycholic acid (Standard) Chenodeoxycholylglycine (Standard)	Reference Standards Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase	Metabolic Disease Cancer
Glycochenodeoxycholic acid (Standard) is the analytical standard of Glycochenodeoxycholic acid. This product is intended for research and analytical applications. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC)[1][2][3][4].

Glycochenodeoxycholic acid sodium salt (Standard) Chenodeoxycholylglycine sodium salt (Standard); Sodium glycochenodeoxycholate (Standard)	Reference Standards Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase	Metabolic Disease Cancer
Glycochenodeoxycholic acid sodium salt (Standard) is the analytical standard of Glycochenodeoxycholic acid sodium salt. This product is intended for research and analytical applications. Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .

T7 Peptide Tumstatin (74-98), human	Integrin FAK mTOR Apoptosis	Cancer
T7 Peptide is a protein synthesis inhibitor and anti-angiogenic agent, with a K_d of 10 nM for human transferrin receptor. T7 Peptide inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelial cells. T7 Peptide induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma .

T7 Peptide TFA Tumstatin (74-98), human TFA	Integrin FAK mTOR Apoptosis	Cancer
T7 Peptide TFA is a protein synthesis inhibitor and anti-angiogenic agent, with a K_d of 10 nM for human transferrin receptor. T7 Peptide TFA inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelial cells. T7 Peptide TFA induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide TFA is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma .

Anti-GPC3 Antibody (YP7)	Glycoprotein VI	Cancer
Anti-GPC3 Antibody (YP7) is a kind of mouse IgG1 κ chimeric antibody, targeting to human GPC3. Anti-GPC3 Antibody (YP7) reacts with the C-lobe of cell surface-associated glypican-3 (GPC3). Anti-GPC3 Antibody (YP7) can be used for the research of cancer, such as hepatocellular carcinoma (HCC) .

MCOPPB trihydrochloride 1 Publications Verification	Opioid Receptor Autophagy	Cardiovascular Disease Neurological Disease
MCOPPB trihydrochloride is a NOP/ORL1 G protein-coupled receptor agonist and autophagy inhibitor that can cross the blood-brain barrier. MCOPPB trihydrochloride clears senescent cells, regulates locomotion, lipid storage and immune responses, and inhibits fibrosis and angiogenesis. MCOPPB trihydrochloride blocks autophagic flux, induces changes in locomotion and lipid storage, and activates the stress-responsive immune transcription network, thereby improving post-infarction cardiac function and exerting anxiolytic effects. MCOPPB trihydrochloride can be applied to research fields such as aging-related diseases and ischemic heart failure .

CHM-1 NSC656158	Microtubule/Tubulin	Cancer
CHM-1, a microtubule-destabilizing agent, inhibits tubulin polymerization. CHM-1 is a potent and selective antimitotic antitumor activity against human hepatocellular carcinoma. CHM-1 induces growth inhibition and apoptosis via G₂-M phase arrest in human hepatocellular carcinoma cells by activation of Cdc2 kinase activity .

MI1013	PROTACs Cytochrome P450 Pregnane X Receptor (PXR)	Metabolic Disease
MI1013 is a PROTAC PXR degrader (DC₅₀ = 89 nM, D_max = 82%). MI1013 degrades PXR in human hepatocellular carcinoma RG cells (HepaRG). MI1013 specifically and safely regulates CYP3A4 promoter activity through PXR degradation. MI1013 affects several key genes involved in sulfate conjugation (e.g., SULT1E1), bile acid synthesis (CYP7A1), gluconeogenesis (PCK1), ketone synthesis (HMGCS20), and hepatocyte proliferation (MKI67). (Pink: PXR ligand 3: HY-175267, Blue: Pomalidomide-propargyl ligand: HY-W410002, Pink + Black: PXR ligand-Linker Conjugate 1: HY-175268) .

Dryocrassin ABBA 2 Publications Verification Dryocrassin	Apoptosis Influenza Virus	Cancer
Dryocrassin ABBA (Dryocrassin) is an orally active phloroglucinol derivative that can be extracted from Phyllopteris officinalis. Dryocrassin ABBA has antitumor and antiviral activity. Dryocrassin ABBA induced apoptosis of human hepatocellular carcinoma cells through mitochondrial pathway mediated by Caspase .

Xanthone V1a	Drug Derivative	Cancer
Xanthone V1a, a derivative of Xanthone (HY-N0126), is an antioxidant that can be found in the roots of Cudrania tricuspidata and twig extracts of Maclura fruticosa. Xanthone V1a exerts cytotoxic effects against colon, hepatocellular, and gastric carcinoma cells. Xanthone V1a exhibits scavenging activitys against DPPH and ABTS. Xanthone V1a can be used for the research of colon carcinoma, hepatocellular carcinoma, and gastric carcinoma .

Muurol-4-ene-3,8-dione	Others	Metabolic Disease
Muurol-4-ene-3,8-dione (Compound 2), a sesquiterpene, is one of the main hepatotoxic components in Eupatorium adenophorum. Muurol-4-ene-3,8-dione has an inhibitory effect on the growth of both the normal human hepatocyte cell L02 and the human hepatocellular carcinoma cell HepG2 with IC₅₀ values of 87.52 and 104.48 μM .

Desacetylcinobufotalin Deacetylcinobufotalin	Apoptosis Bcl-2 Family	Inflammation/Immunology Cancer
Desacetylcinobufotalin is an active component isolated from Venenum Bufonis, which exhibits significant cytotoxicity against human hepatocellular carcinoma HepG2 cells (IC₅₀ = 0.0279 µmol/mL). Desacetylcinobufotalin upregulates Bax protein expression, downregulates Bcl-2 protein expression, and induces apoptosis via the mitochondrial pathway. Desacetylcinobufotalin inhibits cancer cell survival, and shows lower cytotoxicity compared to its parent compound Cinobufagin (HY-N0421). Desacetylcinobufotalin can be used in hepatocellular carcinoma-related research .

XZA-1	Acetyl-CoA Carboxylase	Cancer
XZA-1 is a 3-hydroxyacyl-coenzyme A dehydrogenase (HADH) activator. XZA-1 increases the intracellular level of acetoacetyl-CoA, which in turn induces acetoacetylation modification of Chromobox Protein Homolog 4 (CBX4) at lysine 106 (K106). XZA-1 exhibits antitumor effects in a xenograft model of human hepatocellular carcinoma SMMC7721 cells overexpressing CBX4. XZA-1 can be used for the study of hepatocellular carcinoma .

FGFR2 N549K Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 N549K is a mutant of FGFR3. FGFR2 N549K Recombinant Human Active Protein Kinase is a recombinant FGFR4 N535K protein that can be used to study FGFR4 N535K-related functions .

Lanuginosine	Amyloid-β Cholinesterase (ChE) Apoptosis	Neurological Disease Cancer
Lanuginosine is an alkaloid. Lanuginosine can be isolated from the stems of Xylopia laevigata (Annonaceae) and the leaves of Magnolia grandiflora. Lanuginosine induces Apoptosis. Lanuginosine inhibits AChE (IC₅₀: 10.9 μM). Lanuginosine inhibits Aβ aggregation. Lanuginosine exhibits anticancer activity against hepatocellular carcinoma, human promyelocytic leukemia, human chronic myeloid leukemia, melanoma, and brain tumors. Lanuginosine can be used in the research of Alzheimer's disease .

Antiproliferative agent-69	Drug Derivative	Cancer
Antiproliferative agent-69 (Compound 1) is a prenylated kaempferol derivative found in the fresh bud’s fur of Platanus acerifolia. Antiproliferative agent-69 shows significant antiproliferative effects against human breast cancer cells (MCF-7) and human hepatocellular carcinoma cells (Hep-G2) with IC₅₀ values of 38.2 μM and 39.5 μM, respectively. Antiproliferative agent-69 is promising for research of breast cancer and liver cancer .

KD6001	CTLA-4	Cancer
KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC₅₀: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .

PLK1/p38γ-IN-1	Polo-like Kinase (PLK) p38 MAPK	Cancer
PLK1/p38γ-IN-1(compound 14) is a multitarget inhibitors ofPLK1andp38γ. PLK1/p38γ-IN-1inhibits the growth of human hepatocellular carcinoma and hepatoblastoma cells in vitro .

Penicitide A	Endogenous Metabolite	Infection Cancer
Penicitide A is a marine secondary metabolite. Penicitide A shows moderate cytotoxicity against pathogen A. brassicae and the human hepatocellular liver carcinoma (HepG2) cell line .

Diselaginellin B	Apoptosis	Cancer
Diselaginellin B (compound 2) is a natural product isolated from Selaginella Pulvinata, which exhibits anti-proliferative, apoptosis-inducing and antimetastatic activities against human carcinoma hepatocellular cells .

ATWLPPRAANLLMAAS	Apoptosis Ras Raf MEK ERK Caspase PARP Bcl-2 Family	Cancer
ATWLPPRAANLLMAAS is a chimeric peptide with anti-angiogenic and potent anti-tumor effects. ATWLPPRAANLLMAAS can inhibit the proliferation, viability, migration, and invasion of human hepatocellular carcinoma cells, and induce apoptosis. .

Cat. No.	상품명

HY-L101

Anti-Liver Cancer Compound Library

2,838 compounds

Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.

Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.

MCE offers a unique collection of 2,838 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Cat. No.	상품명	Type

HY-W286743

Nε-(Carboxymethyl)-L-lysine

1 Publications Verification

CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine

Biochemical Assay Reagents

Nε-(Carboxymethyl)-L-lysine (CML) is an orally active advanced glycation end product. Nε-(Carboxymethyl)-L-lysine upregulates the expression of PLK1 and CEP20, and induces the activation of RAGE and ERK/NFκB. Nε-(Carboxymethyl)-L-lysine drives centrosome amplification. Nε-(Carboxymethyl)-L-lysine induces malignant transformation of hepatocytes and promotes the development of hepatocellular carcinoma. Nε-(Carboxymethyl)-L-lysine induces epithelial-mesenchymal transition in osteosarcoma cells and enhances their migration and invasion properties .

HY-N7864

Osbond acid

all-cis-4,7,10,13,16-Docosapentaenoic acid

Biochemical Assay Reagents

Docosapentaenoic acid (DPA) is a 22-carbon fatty acid found in fish oil. It is a minor component of total serum unsaturated fatty acids in humans, ranging from 0.1% to 1%, and increasing with dietary supplementation. all-cis-4,7,10,13,16-DPA, also known as Austrian acid, is an isomer of DPA. It is an omega-6 fatty acid formed by the extension and desaturation of arachidonic acid. During fatty acid desaturase syndrome, levels of this fatty acid may be reduced, which may affect development. Upregulated hepatic elongate expression of very long fatty acid protein 6 and elevated levels of very long chain fatty acids, including all-cis 4,7,10,13,16-DPA, are characteristic of nonalcoholic steatohepatitis, a precancerous disease of hepatocellular carcinoma.

HY-Y1269D

Ammonium chloride, for molecular biology

Salmiac, for molecular biology

Biochemical Assay Reagents

Ammonium chloride (Salmiac), for molecular biology is an inhibitor of Slc26a4 and SMAD2. Ammonium chloride, for molecular biology reduces the protein expression level of Slc26a4 in lung tissue, and attenuates ozone-induced increases in proinflammatory cytokines, inflammatory cells, pulmonary resistance, goblet cell hyperplasia, peribronchial inflammation and thiocyanate levels in mouse tissues and bronchoalveolar lavage fluid. Ammonium chloride, for molecular biology decreases the level of phosphorylated SMAD2, inhibits autophagy by reducing autophagy-related proteins, and enhances Cisplatin (HY-17394)-induced cancer cell apoptosis and DNA double-strand breaks. Ammonium chloride, for molecular biology also inhibits the TCA cycle, reduces ATP production, increases glucose utilization, regulates the levels of lactic acid, glutamic acid and ATP, and induces morphological degeneration of neuroblastoma cells. Ammonium chloride, for molecular biology can be used in studies related to ozone-induced airway injury, hepatocellular carcinoma, human cervical cancer, hepatic encephalopathy, Reye syndrome, epilepsy and neurodegenerative diseases .

Cat. No.	상품명	Target	Research Area

HY-P10323

T7 Peptide Tumstatin (74-98), human	Integrin FAK mTOR Apoptosis	Cancer
T7 Peptide is a protein synthesis inhibitor and anti-angiogenic agent, with a K_d of 10 nM for human transferrin receptor. T7 Peptide inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelial cells. T7 Peptide induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma .

HY-P10323A

T7 Peptide TFA Tumstatin (74-98), human TFA	Integrin FAK mTOR Apoptosis	Cancer
T7 Peptide TFA is a protein synthesis inhibitor and anti-angiogenic agent, with a K_d of 10 nM for human transferrin receptor. T7 Peptide TFA inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelial cells. T7 Peptide TFA induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide TFA is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma .

HY-P10832

ATWLPPRAANLLMAAS	Apoptosis Ras Raf MEK ERK Caspase PARP Bcl-2 Family	Cancer
ATWLPPRAANLLMAAS is a chimeric peptide with anti-angiogenic and potent anti-tumor effects. ATWLPPRAANLLMAAS can inhibit the proliferation, viability, migration, and invasion of human hepatocellular carcinoma cells, and induce apoptosis. .

HY-P11618

10P3Me	Glycoprotein VI	Cancer
10P3Me is a Glypican-3 (GPC3)-targeting probe with a K_a of 93.8 nM for the human target. 10P3Me exhibits high binding affinity to GPC3, targets GPC3-positive cells, and serves as an agent for PET imaging. 10P3Me selectively accumulates in GPC3-positive tumor tissues, including subcutaneous xenograft models and orthotopic HepG2-LUC liver cancer models, to achieve precise localization of lesions .

Cat. No.	상품명

HY-K6124

Human Hepatocellular Carcinoma Organoid Kit
MCE Human Hepatocellular Carcinoma Organoid Kit contains Hepatocellular Carcinoma Organoid Basal Medium A, Hepatocellular Carcinoma Organoid Supplement B (50×), Hepatocellular Carcinoma Organoid Supplement C (250×). This product can be used to efficiently construct human hepatocellular carcinoma organoid.

Cat. No.	상품명	Target	Research Area	Image

HY-P99013

Codrituzumab 1 Publications Verification GC33; RO5137382	Glycoprotein VI	Cancer
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (K_d of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .

HY-P99159

Ivuxolimab	Interleukin Related	Cancer
Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4 ⁺ and CD8 ⁺ T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc .

HY-P990297

Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) 1 Publications Verification	CCR HIV	Infection Inflammation/Immunology Cancer
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV .

HY-P99353

Ascrinvacumab 2 Publications Verification Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab); PF-03446962; GT-90001C	Anaplastic lymphoma kinase (ALK)	Cancer
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a K_d value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .

HY-P990841

Anti-pan-Glypican Antibody (HS20)	Glycoprotein VI	Cancer
Anti-pan-Glypican Antibody (HS20) is a kind of human IgG1 κ human antibody, targeting to human pan-Glypican. Anti-pan-Glypican Antibody (HS20) can neutralize the heparan sulfate (HS) chains on GPC3 thereby disrupting the Wnt3a-GPC3 interactions leading to blockade of the Wnt3a/β-catenin signaling. Anti-pan-Glypican Antibody (HS20) can be used for the research of cancer, such as hepatocellular carcinoma (HCC) .

HY-P990840

Anti-GPC3 Antibody (YP7)	Glycoprotein VI	Cancer
Anti-GPC3 Antibody (YP7) is a kind of mouse IgG1 κ chimeric antibody, targeting to human GPC3. Anti-GPC3 Antibody (YP7) reacts with the C-lobe of cell surface-associated glypican-3 (GPC3). Anti-GPC3 Antibody (YP7) can be used for the research of cancer, such as hepatocellular carcinoma (HCC) .

HY-P991566

KD6001	CTLA-4	Cancer
KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC₅₀: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .

HY-P990867

Anti-CD220/Insulin Receptor Antibody (IR 83-22)	Insulin Receptor Akt	Cancer
Anti-CD220/Insulin Receptor Antibody (IR 83-22) is an anti-human CD220/Insulin Receptor IgG1 monoclonal antibody. Anti-CD220/Insulin Receptor Antibody (IR 83-22) can block Akt overactivation caused by Trip13 deficiency. Anti-CD220/Insulin Receptor Antibody (IR 83-22) can be used for research on cancer such as hepatocellular carcinoma (HCC). Anti-CD220/Insulin Receptor Antibody (IR 83-22) often used in western blotting. The recommend isotype control of Anti-CD220/Insulin Receptor Antibody (IR 83-22): Mouse IgG1 kappa, Isotype Control (HY-P99977) .

HY-P992011

CAT-07	Glycoprotein VI	Cancer
CAT-07 is an anti-human GPC3/Glypican 3 antibody. CAT-07 can be used for the research of cancer, such as hepatocellular carcinoma.

HY-P992399

LBL-019	TNF Receptor NF-κB	Cancer
LBL-019 is a humanized IgG1 monoclonal antibody targeting TNFR2. LBL-019 costimulates TNFR2 and activates the NF-κB signaling pathway in an Fc crosslinking-dependent manner. LBL-019 can be used for the research of advanced malignant tumors, including hepatocellular carcinoma and melanoma. The recommended isotype control is human IgG1 kappa (HY-P99001) .

HY-P991883

Metuzumab Licartin; Metuximab; Mehuzumab	Apoptosis CDK Caspase Bcl-2 Family	Cancer
Metuzumab (Licartin) is a human-mouse chimeric IgG1 monoclonal antibody targeting CD147. Metuzumab induces Apoptosis, reduces levels of Cyclin D1, full-length Caspase-3, and Bcl-2, and increases Bax expression. Metuzumab enhances the sensitivity of non-small cell lung cancer (NSCLC) cells to Gemcitabine (HY-17026). Metuzumab is applicable for research on hepatocellular carcinoma and non-small cell lung cancer [1] [2]_.

HY-P992437

PF-03475952	CD44 Apoptosis	Inflammation/Immunology Cancer
PF-03475952 is a fully human IgG2 monoclonal antibody targeting CD44. PF-03475952 binds an epitope in CD44’s constant exons, blocks CD44-hyaluronic acid interaction, reduces cell surface CD44, and does not cross-react with rodent CD44 or LYVE-1. PF-03475952 induces cancer cell apoptosis, inhibits LPS (HY-D1056)-induced leukocyte cytokine release and cancer metastasis, and reduces CD44 expression on circulating CD3+ lymphocytes in cynomolgus monkeys. PF-03475952 can be used for the research of rheumatoid arthritis and hepatocellular carcinoma .

HY-P992457

SAR444200	Glycoprotein VI Interleukin Related	Cancer
SAR444200 is a nanobody T-cell engager targeting GPC3 (glypican-3) and *TCRαβ (T-cell* receptor αβ). SAR444200 has a K_D** of 0.023 nM for human GPC3 and a K_D of 5.2 nM for human TCRαβ. SAR444200 mediates T-cell-dependent cytotoxicity, with high selectivity and killing activity against GPC3-positive tumor cells. SAR444200 binds to GPC3 in a dual-epitope manner, and binds to TCRαβ via its N-terminal nanobody, forming an artificial immunological synapse between T cells and tumor cells. SAR444200 can be used for the research of GPC3 ⁺ solid tumors, including liver cancer, lung squamous cell carcinoma and melanoma .

HY-P992098

Adargiminase NEI-01	Protein Arginine Deiminase	Cancer
Adargiminase (NEI-01) is a modified arginine-depleting enzyme and albumin binder. Adargiminase catalyzes the conversion of arginine to citrulline and ammonia, reduces plasma arginine levels to undetectable levels, and binds to serum albumin from Mus musculus (mouse), Rattus norvegicus (rat), Canis lupus familiaris (dog) and Homo sapiens (human) to extend its half-life. Adargiminase inhibits the viability of ASS1-negative pancreatic cancer cells, and reduces tumor volume and weight. Adargiminase can be used for the research of pancreatic cancer .

Species:	Human (4)
Tag:	T7 (1) SUMO (1) His (3) Strep (1)
Source:	HEK293 (2) E. coli (2)

Cat. No.	Compare	상품명	Species	Source	Image

HY-P704846

	PIGR Protein, Human (HEK293, Twin-Strep) Polymeric Immunoglobulin Receptor; PIgR; Poly-Ig Receptor; hepatocellular carcinoma-Associated Protein TB6; PIGR	Human	HEK293

HY-P71065

	PIGR Protein, Human (G365S, HEK293, His) Polymeric Immunoglobulin Receptor; PIgR; Poly-Ig Receptor; hepatocellular carcinoma-Associated Protein TB6; PIGR	Human	HEK293
	PIGR proteins play a critical role in mediating the selective transcytosis of polymerized IgA and IgM across mucosal epithelial cells, which is critical for mucosal immunity. PIGR binds these immunoglobulins at the basolateral surface, forming a complex that is transported intracellularly and secreted apically. PIGR Protein, Human (G365S, HEK293, His) is the recombinant human-derived PIGR protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P71608

	TGS1 Protein, Human (His-SUMO) Cap specific guanine N2 methyltransferase; Cap-specific guanine-N2 methyltransferase; CLL associated antigen KW 2; CLL-associated antigen KW-2; DKFZp762A163; FLJ22995; HCA137; hepatocellular carcinoma associated antigen 137; hepatocellular carcinoma-associated antigen 137; NCOA6IP; Nuclear receptor coactivator 6 interacting protein; Nuclear receptor coactivator 6-interacting protein; PIMT; PIPMT; PRIP interacting protein PIPMT; PRIP interacting protein with methyltransferase domain; PRIP interacting protein with methyltransferase motif; PRIP-interacting protein with methyltransferase motif; SEREX defined; TGS 1; Tgs1; TGS1_human; Trimethylguanosine synthase; Trimethylguanosine synthase homolog (S. cerevisiae); Trimethylguanosine synthase homolog	Human	E. coli
	TGS1 protein catalyzes the conversion of the 7-monomethylguanosine (m(7)G) cap of small nuclear RNA (snRNA) and small nucleolar RNA (snoRNA) into 2, 2,7-trimethylguanosine (m( 2,2,7)G) Cap structure. The enzyme shows specificity for guanine, with N7 methylation occurring before N2 methylation during the modification process. TGS1 Protein, Human (His-SUMO) is the recombinant human-derived TGS1 protein, expressed by E. coli , with N-His, N-SUMO labeled tag.

HY-P70950

	IGF2BP2 Protein, Human (T7-His) Insulin-Like Growth Factor 2 mRNA-Binding Protein 2; IGF2 mRNA-Binding Protein 2; IMP-2; hepatocellular carcinoma Autoantigen p62; IGF-II mRNA-Binding Protein 2; VICKZ Family Member 2; IGF2BP2; IMP2; VICKZ2	Human	E. coli
	The IGF2BP2 protein is an RNA-binding factor that coordinates the recruitment of target transcripts into cytoplasmic mRNP, promoting mRNA transport and transient storage. It regulates the contact of target transcripts with the translation machinery and protects them from microRNA-mediated degradation. IGF2BP2 Protein, Human (T7-His) is the recombinant human-derived IGF2BP2 protein, expressed by E. coli , with N-T7, C-6*His labeled tag.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

Cat. No.	Compare	상품명	Application	Reactivity	Image

HY-P87381

	MAGED2/BCG1 Antibody (YA7064) 11B6 antibody; BCG 1 antibody; BCG-1 antibody; Breast cancer-associated gene 1 protein antibody; HCA10 antibody; hepatocellular carcinoma-associated protein JCL-1 antibody; JCL 1 antibody; MAGD2_human antibody; MAGE D antibody; MAGE D2 antigen antibody	WB	Human
	MAGED2/BCG1 Antibody (YA7064) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MAGED2/BCG1.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

Cat. No.	상품명		Classification

HY-150750A

ODN M362 sodium		CpG ODNs
ODN M362 sodium is a TLR9 agonist that acts as a vaccine adjuvant. ODN M362 sodium activates mouse splenocytes, induces apoptosis in human hepatocellular carcinoma cells, upregulates proinflammatory cytokines in human hepatocellular carcinoma cells, and inhibits the proliferation of human hepatocellular carcinoma cells. ODN M362 sodium upregulates the expression of TLR9/TLR6, activates downstream signaling pathways via IRAK4 and IRF7, and strongly amplifies antigen-specific cellular immune responses to participate in innate immune activation. ODN M362 sodium can be used in research related to hepatocellular carcinoma and breast cancer .

HY-153492A

Olpasiran sodium AMG 890 sodium; ARC-LPA sodium		siRNAs siRNA drugs
Olpasiran (AMG 890, ARC-LPA) sodium is an N-acetyl galactosamine (GalNAc)-conjugated, hepatocyte-targeted siRNA. Olpasiran sodium directly inhibits LPA messenger RNA translation in hepatocytes and potently reduce Lp(a) concentration. Olpasiran sodium can be used for the research of cardiovascular disease, such as atherosclerosis .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

human hepatocellular carcinoma

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Antibodies

Oligonucleotides

Natural
Products